Statins and total (not LDL) cholesterol concentration and outcome of myocardial infarction: Results from a meta-analysis and an observational study

European Journal of Clinical Pharmacology

Volumn 65, Issue 11, 2009, Pages 1071-1080

  Sheng, Xia ^a   Wei, Li ^a   Murphy, Michael J ^b   MacDonald, Thomas M ^a  

^a UNIVERSITY OF DUNDEE   (United Kingdom)

^b UNIVERSITY OF DUNDEE   (United Kingdom)

Author keywords

Effectiveness; Myocardial infarction; Statin treatment; Total cholesterol concentration

Indexed keywords

ANTICOAGULANT AGENT; ANTITHROMBOCYTIC AGENT; ATORVASTATIN; DIPEPTIDYL CARBOXYPEPTIDASE INHIBITOR; FLUINDOSTATIN; HIGH DENSITY LIPOPROTEIN CHOLESTEROL; HYDROXYMETHYLGLUTARYL COENZYME A REDUCTASE INHIBITOR; LOW DENSITY LIPOPROTEIN CHOLESTEROL; MEVINOLIN; PLACEBO; PRAVASTATIN; SIMVASTATIN; TRIACYLGLYCEROL;

CHOLESTEROL BLOOD LEVEL; CLINICAL TRIAL; HEART INFARCTION; HUMAN; MEASUREMENT; META ANALYSIS; PRIMARY PREVENTION; PRIORITY JOURNAL; REVIEW; RISK REDUCTION; SECONDARY PREVENTION; SYSTEMATIC REVIEW;

CHOLESTEROL; COHORT STUDIES; FEMALE; HUMANS; HYDROXYMETHYLGLUTARYL-COA REDUCTASE INHIBITORS; MALE; MIDDLE AGED; MYOCARDIAL INFARCTION; RISK FACTORS; TREATMENT OUTCOME;

EID: 70350224113     PISSN: 00316970     EISSN: None     Source Type: Journal    
DOI: 10.1007/s00228-009-0720-x     Document Type: Review

References (35)

1. R Collins J Armitage S Parish P Sleight R Peto Heart Protection Study Collaborative Group 2002 MCR/BHF Heart Protection Study of cholesterol lowering with simvastatin in 20536 high-risk individuals Lancet 360 7 22 10.1016/S0140-6736(02)09327-3 (Pubitemid 34756487)
2. FM Sacks LA Moye BR Davis TG Cole JL Rouleau DT Nash MA Pfeffer E Braunwald 1998 Relationship between plasma LDL concentrations during treatment with pravastatin and recurrent coronary events in the cholesterol and recurrent events trial Circulation 97 15 1446 1452 1:CAS:528:DyaK1cXivVWnsbo%3D 9576424
3. Long-term Intervention with Pravastatin in Ischaemic Disease (LIPID) Study Group 2002 Long-term effectiveness and safety of pravastatin in 9014 patients with coronary heart disease and average cholesterol concentrations Lancet 359 1379 1387 10.1016/S0140-6736(02)08351-4 (Pubitemid 34442378)
4. PS Sever B Dahlöf NR Poulter H Wedel G Beevers M Caulfield R Collins SE Kjeldsen A Kristinsson GT McInnes J Mehlsen M Nieminen E O'Brien J Ostergren 2003 ASCOT investigators. Prevention of coronary and stroke events with atorvastatin in hypertensive patients who have average or lower-than-average cholesterol concentrations, in the Anglo-Scandinavian Cardiac Outcomes Trial-Lipid Lowering Arm (ASCOT-LLA) Lancet 361 1149 1158 10.1016/S0140-6736(03) 12948-0 1:CAS:528:DC%2BD3sXis1yqu7o%3D 12686036 (Pubitemid 36398384)
5. FM Sacks MA Pfeffer LA Moye JL Rouleau JD Rutherford TG Cole L Brown JW Warnica JM Arnold CC Wun BR Davis E Braunwald 1996 The effect of pravastatin on coronary events after myocardial infarction in patients with average cholesterol levels. Cholesterol and Recurrent Events Trial investigators (CARE) N Engl J Med 335 14 1001 1009 10.1056/NEJM199610033351401 1:CAS:528:DyaK28XmsFWls7c%3D 8801446 (Pubitemid 26338729)
6. J Shepherd GJ Blauw MB Murphy EL Bollen BM Buckley SM Cobbe I Ford A Gaw M Hyland JW Jukema AM Kamper PW Macfarlane AE Meinders J Norrie CJ Packard IJ Perry DJ Stott BJ Sweeney C Twomey RG Westendorp 2002 Pravastatin in elderly individuals at risk of vascular disease (PROSPER) Lancet 360 1623 1630 10.1016/S0140-6736(02)11600-X 1:CAS:528:DC%2BD38XovFegt7o%3D 12457784 (Pubitemid 35379733)
7. PW Serruys P de Feyter C Macaya N Kokott J Puel M Vrolix A Branzi MC Bertolami G Jackson B Strauss B Meier Lescol Intervention Prevention Study Lescol Intervention Prevention Study (LIPS) Investigators 2002 Fluvastatin for prevention of cardiac events following successful first percutaneous coronary intervention: a randomized controlled trial JAMA 287 3215 3222 10.1001/jama.287.24.3215 1:CAS:528:DC%2BD38XkvVOjtr8%3D 12076217
8. The Long-term Intervention with Pravastatin in Ischaemic Disease (LIPID) Study Group 1998 Prevention of cardiovascular events and death with pravastatin in patients with coronary heart disease and a broad range of initial cholesterol levels N Engl J Med 339 1349 1357 10.1056/NEJM199811053391902 (Pubitemid 28509344)
9. J Shepherd SM Cobbe I Ford CG Isles AR Lorimer PW MacFarlane JH McKillop CJ Packard West of Scotland Coronary Prevention Study Group 1995 Prevention of coronary heart disease with pravastatin in men with hypercholesterolemia N Engl J Med 333 1301 1307 10.1056/NEJM199511163332001 1:CAS:528:DyaK28Xhslemsw%3D%3D 7566020
10. C Baigent A Keech PM Kearney L Blackwell G Buck C Pollicino A Kirby T Sourjina R Peto R Collins R Simes Cholesterol Treatment Trialists' (CTT) Collaborators 2005 Efficacy and safety of cholesterol-lowering treatment: prospective meta-analysis of data from 90 056 participants in 14 randomised trials of statins Lancet 366 9493 1267 1278 10.1016/S0140-6736(05)67394-1 1:CAS:528:DC%2BD2MXhtVOlu7fM 16214597 (Pubitemid 41416582)
11. M Vrecer S Turk J Drinovec A Mrhar 2003 Use of statins in primary and secondary prevention of coronary heart disease and ischemic stroke. Meta-analysis of randomized trials Int J Clin Pharmacol Ther 41 12 567 577 1:CAS:528:DC%2BD2cXht1Kqug%3D%3D 14692706
12. MJ Murphy L Wei AD Waston TM Macdonald 2008 'Real-life' reduction in cholesterol with statins, 1993 to 2002 Br J Clin Pharmacol 65 4 587 592 10.1111/j.1365-2125.2007.03066.x 1:CAS:528:DC%2BD1cXlt1Cgsbk%3D 18241286
13. M Blettner W Sauerbrei B Schlehofer T Scheuchenpflug C Friedenreich 1999 Traditional reviews, meta-analyses and pooled analyses in epidemiology Int J Epidemiol 28 1 9 10.1093/ije/28.1.1 1:STN:280:DyaK1M3htVSgsA%3D%3D 10195657 (Pubitemid 29086203)
14. Wei L, Parkinson J, Macdonald TM (2005) The Tayside Medicines Monitoring Unit (MEMO). In: Strom BL (ed) Pharmacoepidemiology, 4th edn. Wiley, Chichester, pp 323-336
15. A Tamura Y Mikuriya M Nasu 1997 Effect of pravastatin (10 mg/day) on progression of coronary atherosclerosis in patients with serum total cholesterol levels from 160 to 220 mg/dl and angiographically documented coronary artery disease. Coronary Artery Regression Study (CARS) Group Am J Cardiol 79 7 893 896 10.1016/S0002-9149(97)00010-6 1:CAS:528:DyaK2sXivVygtrk%3D 9104901 (Pubitemid 27197921)
16. The Pravastatin Multinational Study Group for Cardiac Risk Patients 1993 Effects of pravastatin in patients with serum total cholesterol levels from 5.2 to 7.8 mmol/liter (200 to 300 mg/dl) plus two additional atherosclerotic risk factors Am J Cardiol 72 14 1031 1037 10.1016/0002-9149(93)90858-A (Pubitemid 23319926)
17. B Pitt GB Mancini SG Ellis HS Rosman JS Park ME McGovern 1995 Pravastatin limitation of atherosclerosis in the coronary arteries (PLAC I): reduction in atherosclerosis progression and clinical events. PLAC I investigation J Am Coll Cardiol 26 5 1133 1139 10.1016/0735-1097(95)00301-0 1:CAS:528:DyaK28XjsFCm 7594023
18. JR Crouse III RP Byington MG Bond MA Espeland TE Craven JW Sprinkle ME McGovern CD Furberg 1995 Pravastatin, lipids, and atherosclerosis in the carotid arteries (PLAC-II) Am J Cardiol 75 7 455 459 10.1016/S0002-9149(99)80580-3 7863988
19. JW Jukema AV Bruschke AJ van Boven JH Reiber ET Bal AH Zwinderman H Jansen GJ Boerma FM van Rappard KI Lie 1995 Effects of lipid lowering by pravastatin on progression and regression of coronary artery disease in symptomatic men with normal to moderately elevated serum cholesterol levels. The Regression Growth Evaluation Statin Study (REGRESS) Circulation 91 10 2528 2540 1:STN:280:DyaK2M3mt1ahuw%3D%3D 7743614
20. Scandinavian Simvastatin Survival Study Group 1994 Randomised trial of cholesterol lowering in 4444 patients with coronary heart disease: the Scandinavian Simvastatin Survival Study (4S) Atheroscler Suppl 5 3 81 87
21. MAAS Investigators 1994 Effect of simvastatin on coronary atheroma: the Multicentre Anti-Atheroma Study (MAAS) Lancet 344 8923 633 638 10.1016/S0140-6736(94)92082-6 (Pubitemid 24274306)
22. KK Teo JR Burton CE Buller S Plante D Catellier W Tymchak V Dzavik D Taylor S Yokoyama TJ Montague 2000 Long-term effects of cholesterol lowering and angiotensin-converting enzyme inhibition on coronary atherosclerosis: the Simvastatin/Enalapril Coronary Atherosclerosis Trial (SCAT) Circulation 102 15 1748 1754 1:CAS:528:DC%2BD3cXnsF2msbs%3D 11023927
23. DH Blankenhorn SP Azen DM Kramsch WJ Mack L Cashin-Hemphill HN Hodis LW DeBoer PR Mahrer MJ Masteller LI Vailas P Alaupovic LJ Hirsch MARS Research Group 1993 Coronary angiographic changes with lovastatin therapy. The Monitored Atherosclerosis Regression Study (MARS) Ann Intern Med 119 10 969 976 1:STN:280:DyaK2c%2FivVertw%3D%3D 8214993
24. D Waters J Lespérance P Gladstone SJ Boccuzzi T Cook R Hudgin G Krip L Higginson 1996 Effects of cigarette smoking on the angiographic evolution of coronary atherosclerosis. A Canadian Coronary Atherosclerosis Intervention Trial (CCAIT) Substudy. CCAIT Study Group Circulation 94 4 614 621 1:STN:280:DyaK28zmvVKksw%3D%3D 8772679
25. JA Herd CM Ballantyne JA Farmer JJ Ferguson III PH Jones MS West KL Gould AM Gotto Jr 1997 Effects of fluvastatin on coronary atherosclerosis in patients with mild to moderate cholesterol elevations (Lipoprotein and Coronary Atherosclerosis Study [LCAS]) Am J Cardiol 80 278 286 10.1016/S0002-9149(97) 00346-9 1:CAS:528:DyaK2sXls1Wrt70%3D 9264419 (Pubitemid 27330142)
26. G Riegger C Abletshauser M Ludwig P Schwandt J Widimsky G Weidinger D Welzel 1999 The effect of fluvastatin on cardiac events in patients with symptomatic coronary artery disease during one year of treatment Atherosclerosis 144 1 263 270 10.1016/S0021-9150(99)00062-3 1:CAS:528:DyaK1MXkt1eltrY%3D 10381299 (Pubitemid 29259987)
27. CD Furberg HP Adams Jr WB Applegate RP Byington MA Espeland T Hartwell DB Hunninghake DS Lefkowitz J Probstfield WA Riley 1994 Effect of lovastatin on early carotid atherosclerosis and cardiovascular events. Asymptomatic Carotid Artery Progression Study (ACAPS) research group Circulation 90 4 1679 1687 1:STN:280:DyaK2M%2FgvVSqsw%3D%3D 7734010
28. JR Downs M Clearfield S Weis E Whitney DR Shapiro PA Beere A Langendorfer EA Stein W Kruyer AM Gotto Jr 1998 Primary prevention of acute coronary events with lovastatin in men and women with average cholesterol levels: results of AFCAPS/TexCAPS. Air Force/Texas Coronary Atherosclerosis Prevention Study JAMA 279 20 1615 1622 10.1001/jama.279.20.1615 1:STN:280:DyaK1c3ntl2qsw%3D%3D 9613910 (Pubitemid 28248586)
29. R Salonen K Nyyssönen E Porkkala J Rummukainen R Belder JS Park JT Salonen Kuopio Atherosclerosis Prevention Study (KAPS) 1995 A population-based primary preventive trial of the effect of LDL lowering on atherosclerotic progression in carotid and femoral arteries Circulation 92 7 1758 1764 1:STN:280:DyaK2MvgtFehuw%3D%3D 7671358
30. J Shepherd SM Cobbe I Ford CG Isles AR Lorimer PW MacFarlane JH McKillop CJ Packard 2004 Prevention of coronary heart disease with pravastatin in men with hypercholesterolemia Atheroscler Suppl 5 3 91 97 10.1016/j. atherosclerosissup.2004.08.029 1:CAS:528:DC%2BD2cXptl2lt7k%3D 15531281
31. HP Bestehorn UF Rensing H Roskamm P Betz L Benesch K Schemeitat G Blümchen J Claus P Mathes L Kappenberger H Wieland A Neiss 1997 The effect of simvastatin on progression of coronary artery disease. The Multicenter Coronary Intervention Study (CIS) Eur Heart J 18 2 226 234 1:STN:280: DyaK2s7ps1Onuw%3D%3D 9043838
32. HM Colhoun DJ Betteridge PN Durrington GA Hitman HA Neil SJ Livingstone MJ Thomason MI Mackness V Charlton-Menys JH Fuller CARDS investigators 2004 Primary prevention of cardiovascular disease with atorvastatin in type 2 diabetes in the Collaborative Atorvastatin Diabetes Study (CARDS): multicentre randomised placebo-controlled trial Lancet 364 9435 685 696 10.1016/S0140- 6736(04)16895-5 1:CAS:528:DC%2BD2cXmvFWltrY%3D 15325833 (Pubitemid 39140624)
33. BB Dean JE Borenstein JM Henning K Knight CN Merz 2004 Can change in high-density lipoprotein cholesterol levels reduce cardiovascular risk? Am Heart J 147 6 966 976 10.1016/j.ahj.2003.10.051 1:CAS:528:DC%2BD2cXltVKhu7s%3D 15199342 (Pubitemid 38880949)
34. L Wei S Ebrahim C Bartlett PD Davey FM Sullivan TM MacDonald 2005 Statin use in the secondary prevention of coronary heart disease in primary care: cohort study and comparison of inclusion and outcome with patients in randomized trials BMJ 330 821 10.1136/bmj.38398.408032.8F 15790616 (Pubitemid 40529803)
35. DJ Graham JA Staffa D Shatin SE Andrade SD Schech L La Grenade JH Gurwitz KA Chan MJ Goodman R Platt 2004 Incidence of hospitalized rhabdomyolysis in patients treated with lipid-lowering drugs JAMA 292 21 2585 2590 10.1001/jama.292.21.2585 1:CAS:528:DC%2BD2cXhtVegurzM 15572716 (Pubitemid 39577514)